Q1 Earnings Estimate for QNRX Issued By Zacks Small Cap

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) – Equities researchers at Zacks Small Cap issued their Q1 2025 EPS estimates for shares of Quoin Pharmaceuticals in a note issued to investors on Monday, March 17th. Zacks Small Cap analyst M. Marin expects that the company will post earnings per share of ($0.11) for the quarter. The consensus estimate for Quoin Pharmaceuticals’ current full-year earnings is ($2.05) per share. Zacks Small Cap also issued estimates for Quoin Pharmaceuticals’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.11) EPS.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its earnings results on Thursday, March 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.15.

Quoin Pharmaceuticals Trading Up 1.5 %

Shares of NASDAQ:QNRX opened at $0.30 on Wednesday. Quoin Pharmaceuticals has a 12-month low of $0.27 and a 12-month high of $1.57. The business has a 50-day moving average price of $0.37 and a 200 day moving average price of $0.55. The company has a market capitalization of $1.51 million, a price-to-earnings ratio of -0.07 and a beta of 1.82.

Insiders Place Their Bets

In related news, CFO Gordon Dunn purchased 122,221 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were bought at an average price of $0.45 per share, for a total transaction of $54,999.45. Following the acquisition, the chief financial officer now directly owns 151,077 shares in the company, valued at $67,984.65. This trade represents a 423.55 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Anthony James Culverwell purchased 100,000 shares of Quoin Pharmaceuticals stock in a transaction on Monday, December 23rd. The stock was bought at an average cost of $0.45 per share, for a total transaction of $45,000.00. Following the transaction, the director now directly owns 100,317 shares in the company, valued at $45,142.65. This represents a 31,545.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 777,777 shares of company stock worth $350,000 over the last ninety days. Corporate insiders own 3.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Apollon Wealth Management LLC acquired a new stake in shares of Quoin Pharmaceuticals in the 4th quarter valued at $52,000. Boothbay Fund Management LLC purchased a new position in Quoin Pharmaceuticals in the fourth quarter valued at $53,000. Renaissance Technologies LLC raised its stake in Quoin Pharmaceuticals by 244.1% in the fourth quarter. Renaissance Technologies LLC now owns 133,122 shares of the company’s stock valued at $87,000 after buying an additional 94,431 shares in the last quarter. Finally, Altium Capital Management LLC acquired a new position in shares of Quoin Pharmaceuticals during the 4th quarter worth about $184,000. Institutional investors and hedge funds own 8.63% of the company’s stock.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.